

Teva Canada Limited | Media Statement | December 14, 2024

## **<sup>17</sup>C TEVA-CLOBAZAM 10 mg TABLETS SUPPLY**

Teva Canada Limited is currently experiencing a backorder on <sup>17</sup>C TEVA-CLOBAZAM 10 mg Tablets with an expected return to market in April 2025, as reported on Health Canada's Drug Shortage Database<sup>1</sup>. The root cause of our backorder is linked to the complex international supply chain for the various components of the product including a delay in receiving the required active pharmaceutical ingredient (API) from our supplier in Europe. We continue to explore every option to speed its return to market.

<sup>17</sup>C TEVA-CLOBAZAM (clobazam) is indicated for adjunctive therapy in patients with epilepsy who are not adequately stabilized with their current anticonvulsant therapy<sup>2</sup>.

We are diligently working to expedite our return to the market recognizing the importance of this medicine to patients living with epilepsy. In the meantime, we recommend that patients consult with their healthcare professional to explore available treatment options.

At Teva Canada, we work together to help patients get the medicine they need. Our goal is to provide innovative treatments and quality generic and biosimilar medicines to the patients, families and communities we touch every day. Teva medicines are used to fill over 160,000 prescriptions daily<sup>3</sup> in Canada and generated over \$1.2 billion<sup>4</sup> in healthcare system savings in 2023.

### **Drug Shortages | Additional information**

For additional information and background on drug shortages in Canada, please use the links below:

#### **Canadian Generic Pharmaceutical Association**

<https://canadiangenerics.ca/medicines/drug-shortages/>

This webpage provides answers to frequently asked questions surrounding drug shortages.

#### **Drug Shortages Canada**

<https://www.drugshortagescanada.ca/>

The website for reporting drug shortages and discontinuations in Canada. The Food and Drug Regulations require drug sellers to report when they are not able to meet demand for a product or when they stop selling a product.

#### **Health Canada | Drug shortages in Canada**

<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages.html>

This webpage provides an overview of drug shortages in Canada and includes a link to Health Canada's most recent drug shortage report: *Building resilience: Health Canada's plan to address health product shortages, 2024 to 2028* (published June 2024) This report outlines a framework for managing the complexities of drug shortages and Teva Canada is aligned to the strategies proposed.

---

<sup>1</sup> Source: Drug Shortages Canada - <https://www.drugshortagescanada.ca/shortage/229230>

<sup>2</sup> Source: Product Monograph, December 22, 2021, Teva Canada Limited - [https://pdf.hres.ca/dpd\\_pm/00064104.PDF](https://pdf.hres.ca/dpd_pm/00064104.PDF)

<sup>3</sup> Source: IQVIA, Compuscript May 2024 MAT

<sup>4</sup> Source: Teva ESG Report 2023 - <https://www.tevapharm.com/globalassets/tevapharm-vision-files/teva-esg-progress-report-2023.pdf>

*Note: This information was provided by and attributed to Teva Canada Limited. Employees of Relevants Inc. are not authorized spokespersons for Teva Canada.*